Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00061945 · OUTCOME

Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)

Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia · Source last updated 2022-05-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
8 months

What was measured

The primary endpoint is the number of participants who are able to proceed to course V within two - six weeks of completion of course IV.

Analysis population: Only participants who started Alemtuzumab were analyzed per study design. Specifically, one patient declined Alemtuzumab and was excluded from this analysis.

Groups in this outcome

Phase II - Alemtuzumab and Combination Chemotherapy

See detailed description or participant flow.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Phase II - Alemtuzumab and Combination Chemotherapy65

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Phase II - Alemtuzumab and Combination Chemotherapy30Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        30
denoms
  1. counts
    1. group Id
      OG000
      value
      65
    units
    Participants
description
The primary endpoint is the number of participants who are able to proceed to course V within two - six weeks of completion of course IV.
groups
  1. description
    See detailed description or participant flow.
    id
    OG000
    title
    Phase II - Alemtuzumab and Combination Chemotherapy
param Type
NUMBER
population Description
Only participants who started Alemtuzumab were analyzed per study design. Specifically, one patient declined Alemtuzumab and was excluded from this analysis.
reporting Status
POSTED
time Frame
8 months
title
Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice